Loading
Delivered the first gene-edited off-the-shelf CAR-T cells to infants with leukaemia and the first base-edited CAR-T therapy.
Waseem Qasim led the compassionate use and then trials of UCART19, TALEN-edited universal donor CAR T cells, in infants and children with refractory ALL, the first clinical use of gene-edited allogeneic CAR-T. In 2023 his team reported the first patient treated with base-edited CAR7 T cells for T-cell ALL, a disease where autologous CAR-T is impractical. He leads cell and gene therapy at Great Ormond Street.
Shares CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia and the tags cell-therapy, paediatric.
Shares Allogeneic (off-the-shelf) cell therapy, CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia.
Shares CAR-T cell therapy and the tags cell-therapy, paediatric.
Shares Allogeneic (off-the-shelf) cell therapy, CD19, CAR-T cell therapy and the tag cell-therapy.
Shares CRISPR functional genomics, Allogeneic (off-the-shelf) cell therapy, CD19, CAR-T cell therapy.
Shares CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia.
Shares UCART19: the first gene-edited, donor-derived CAR-T cells in children and adults with relapsed B-cell ALL, Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy.
Shares CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia and the tag cell-therapy.